Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study

Key Takeaways SNY said its phase III LEAP2MONO study met all primary endpoints in GD3 patients versus ERT.Sanofi reported significant, clinically meaningful neurological gains at 52 weeks on SARA and RBANS.SNY said venglustat improved spleen and liver size, was well tolerated, and will advance to filings.Sanofi (SNY) announced that a late-stage study, evaluating venglustat, an investigational oral glucosylceramide synthase inhibitor (GCSi), in patients aged 12 years and older with type 3 Gaucher disease (GD ...